TCGX Acquisition (TCGX) News
NASDAQ: TCGXFinanceBlank ChecksUSD
10.02-0.005 (-0.05%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TCGX news summary
We found 3 recent headlines mentioning TCGX Acquisition (TCGX): 0 in the past week and 1 in the past 30 days, most often from Business Wire. For price context, TCGX is down 0.05% at $10.02. The most recent story, "TriGemX Bio and TCGX Acquisition Corp. Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination", was published by Business Wire on Nov 2, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest TCGX Acquisition headlines
- TriGemX Bio and TCGX Acquisition Corp. Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business CombinationNEW YORK & PALO ALTO, Calif.--(BUSINESS WIRE)-- #Biotechnology--TriGemX Bio, Inc. (“TriGemX Bio”), a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for…Business Wire
- TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Company to Develop Elismetrep, A Potential First-in-Class Treatment for MigraineNEW YORK & PALO ALTO, Calif.--(BUSINESS WIRE)--TriGemX Bio, a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX Acquisition Corp.…Business Wire
- TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Company to Develop Elismetrep, a Potential First-in-Class Treatment for MigraineNEW YORK & PALO ALTO, Calif.--(BUSINESS WIRE)-- #Biotechnology--TriGemX Bio, a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX…Business Wire